The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase Ib/II BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 (Medical Xpress) - Sep 12, 2026 - "Among 71 efficacy-evaluable patients with SCLC as of July 7, 2026, one patient achieved a complete response, 49 achieved partial responses and 16 had stable disease...The overall objective response rate across all doses was 70.4%, and the disease control rate was 93.0%...Response rates varied by treatment line: 92.3% in first-line SCLC, 77.3% in second-line disease and 52.4% in patients treated in the third line or later."
P1/2 data • Lung Neuroendocrine Carcinoma • Small Cell Lung Cancer
|